Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 67

1.

Dynamical effects of epigenetic silencing of 14-3-3sigma expression.

Vera J, Schultz J, Ibrahim S, Raatz Y, Wolkenhauer O, Kunz M.

Mol Biosyst. 2010 Jan;6(1):264-73. doi: 10.1039/b907863k. Epub 2009 Sep 25.

PMID:
20024089
2.

Roles for negative cell regulator 14-3-3sigma in control of MDM2 activities.

Yang HY, Wen YY, Lin YI, Pham L, Su CH, Yang H, Chen J, Lee MH.

Oncogene. 2007 Nov 15;26(52):7355-62. Epub 2007 Jun 4.

PMID:
17546054
3.

14-3-3sigma gene silencing during melanoma progression and its role in cell cycle control and cellular senescence.

Schultz J, Ibrahim SM, Vera J, Kunz M.

Mol Cancer. 2009 Jul 30;8:53. doi: 10.1186/1476-4598-8-53.

4.

Model-based investigation of the transcriptional activity of p53 and its feedback loop regulation via 14-3-3σ.

Vera J, Nikolov S, Lai X, Singh A, Wolkenhauer O.

IET Syst Biol. 2011 Sep;5(5):293-307. doi: 10.1049/iet-syb.2010.0080.

PMID:
22010756
5.

Prostate cancer is characterized by epigenetic silencing of 14-3-3sigma expression.

Lodygin D, Diebold J, Hermeking H.

Oncogene. 2004 Dec 2;23(56):9034-41.

PMID:
15489902
6.

14-3-3sigma mediation of cell cycle progression is p53-independent in response to insulin-like growth factor-I receptor activation.

Zhang Y, Karas M, Zhao H, Yakar S, LeRoith D.

J Biol Chem. 2004 Aug 13;279(33):34353-60. Epub 2004 Jun 8.

7.

Epigenetic mechanisms of irinotecan sensitivity in colorectal cancer cell lines.

Crea F, Giovannetti E, Cortesi F, Mey V, Nannizzi S, Gallegos Ruiz MI, Ricciardi S, Del Tacca M, Peters GJ, Danesi R.

Mol Cancer Ther. 2009 Jul;8(7):1964-73. doi: 10.1158/1535-7163.MCT-09-0027. Epub 2009 Jun 16.

8.

Epigenetic silencing of 14-3-3sigma in cancer.

Lodygin D, Hermeking H.

Semin Cancer Biol. 2006 Jun;16(3):214-24. Epub 2006 Apr 1. Review.

PMID:
16698281
10.

Multiple p53-independent gene silencing mechanisms define the cellular response to p53 activation.

París R, Henry RE, Stephens SJ, McBryde M, Espinosa JM.

Cell Cycle. 2008 Aug;7(15):2427-33. Epub 2008 Jun 9.

11.

Epigenetic and proteolytic inactivation of 14-3-3sigma in breast and prostate cancers.

Horie-Inoue K, Inoue S.

Semin Cancer Biol. 2006 Jun;16(3):235-9. Epub 2006 Apr 1. Review.

PMID:
16682214
12.

Mdm2 deficiency suppresses MYCN-Driven neuroblastoma tumorigenesis in vivo.

Chen Z, Lin Y, Barbieri E, Burlingame S, Hicks J, Ludwig A, Shohet JM.

Neoplasia. 2009 Aug;11(8):753-62.

13.

Interplay between p53-family, their regulators, and PARPs in DNA repair.

Emami S.

Clin Res Hepatol Gastroenterol. 2011 Feb;35(2):98-104. doi: 10.1016/j.gcb.2010.10.002. Epub 2010 Dec 21. Review.

PMID:
21177056
14.

14-3-3sigma exerts tumor-suppressor activity mediated by regulation of COP1 stability.

Su CH, Zhao R, Zhang F, Qu C, Chen B, Feng YH, Phan L, Chen J, Wang H, Wang H, Yeung SC, Lee MH.

Cancer Res. 2011 Feb 1;71(3):884-94. doi: 10.1158/0008-5472.CAN-10-2518. Epub 2010 Dec 6.

15.

Cooperative effect of p21Cip1/WAF-1 and 14-3-3sigma on cell cycle arrest and apoptosis induction by p14ARF.

Hemmati PG, Normand G, Gillissen B, Wendt J, Dörken B, Daniel PT.

Oncogene. 2008 Dec 4;27(53):6707-19. doi: 10.1038/onc.2008.193. Epub 2008 Sep 22.

PMID:
18806827
16.

Explaining oscillations and variability in the p53-Mdm2 system.

Proctor CJ, Gray DA.

BMC Syst Biol. 2008 Aug 18;2:75. doi: 10.1186/1752-0509-2-75.

17.

The 14-3-3sigma gene promoter is methylated in both human melanocytes and melanoma.

Liu S, Howell P, Ren S, Fodstad O, Riker AI.

BMC Cancer. 2009 May 27;9:162. doi: 10.1186/1471-2407-9-162.

18.

Direct interaction with and activation of p53 by SMAR1 retards cell-cycle progression at G2/M phase and delays tumor growth in mice.

Kaul R, Mukherjee S, Ahmed F, Bhat MK, Chhipa R, Galande S, Chattopadhyay S.

Int J Cancer. 2003 Feb 20;103(5):606-15.

19.

Alterations of the p16-pRb pathway and the chromosome locus 9p21-22 in non-small-cell lung carcinomas: relationship with p53 and MDM2 protein expression.

Gorgoulis VG, Zacharatos P, Kotsinas A, Liloglou T, Kyroudi A, Veslemes M, Rassidakis A, Halazonetis TD, Field JK, Kittas C.

Am J Pathol. 1998 Dec;153(6):1749-65.

20.

Elevated MDM2 boosts the apoptotic activity of p53-MDM2 binding inhibitors by facilitating MDMX degradation.

Xia M, Knezevic D, Tovar C, Huang B, Heimbrook DC, Vassilev LT.

Cell Cycle. 2008 Jun 1;7(11):1604-12. Epub 2008 Mar 17.

PMID:
18520179

Supplemental Content

Support Center